Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients
Article Abstract:
A 4-drug induction was tested followed by 3-drug maintenance as initial antiretroviral therapy (ART) to reduce HIV RNA rapidly and then to simplify to an effective yet more convenient and tolerable regime. It was found that after induction with abacavir/lamivudine/zidovudine + efavirenz (ABC/3TC/ZDV + EFV), simplification to ABC/3TC/ZDV alone maintained virologic control and immunologic response, reduced fasting lipids and ART-associated adverse events, and improved adherence.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults
Article Abstract:
A randomized double-blind clinical trial compared the efficacy and safety of 600mg of abacavir (ABC) administered once daily versus 300mg of ABC administered twice daily n combination with 300 mg of lamivudine (3TC) and 600 mg of efavirenz (EFV) administered once daily in antiretroviral-naive patients over 48 weeks. The ABC once-daily and twice-daily regimens were similar with respect to infrequency of virologic failure, and emergence of resistarnce mutations.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients
Article Abstract:
A study conducted examined the efficacy and tolerability of 2 regimens composed of efavirenz (EFV) plus twice-daily fixed-dose zidovudine (ZDV)/lamivudine (3TC) or once-daily tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) over 96 weeks. It is concluded that over 96 weeks, the combination of TDF, FTC, and EFV was superior to fixed-dose ZDV/3TC + EFV for achieving and maintaining an HIV RNA level < 400 copies/mL and an increase in CD4 cells.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Increased body mass index does not alter response to initial highly active antiretroviral therapy in HIV-1-infected patients
- Abstracts: Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL)
- Abstracts: Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients
- Abstracts: Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients
- Abstracts: Assessing mixed venous and arterial leg ulcers. Diagnosing, treating, and delivering care for people with venous leg ulcers